This multicentre, randomised, double-blind, placebo controlled trial will evaluate the clinical effectiveness of SLT for the symptomatic improvement of VaD in 226 patients with mild to moderate probable VaD or Alzheimer’s disease with cerebrovascular disease (AD+CVD).
Specifically, the objectives of the study are to determine the efficacy of the herbal intervention on cognitive function, activities of daily living, and quality of life, and monitor the safety of SLT as a treatment for VaD or AD+CVD during 52 weeks.
We hypothesise that a 52 week treatment of SLT as compared with placebo will be clinically effective and well tolerated in patients with VaD or AD+CVD. The design of this study follows the European Medicines Agency’s Guidelines on Medicinal Products for the Treatment Of Alzheimer’s Disease and other Dementia.
The National Institute of Complementary Medicine